Latest Intelligence on Therapy Area in South and Central America

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
ResearchWire
ResearchWire

Antithrombotics: blockbuster potential for novel anticoagulants

Published By Datamonitor
31 May 2007
ResearchWire
ResearchWire

Anxiety disorders: global sales set to slide

Published By Datamonitor
03 May 2006
CommentWire
CommentWire

APA 2010: Alkermes prepares to enter potentially lucrative opioid dependence market

At this year's American Psychiatric Association meeting, US pharmaceutical company Alkermes presented promising new data for Vivitrol in the treatment of opioid dependence. The FDA is currently assessing the drug under a priority review, and approval in the burgeoning opioid dependence indication would be a major boon for Alkermes.

Published By Datamonitor
10 Jun 2010
Expert View
Expert View

APA 2010: limited data highlight unmet needs in bipolar disorder

Several leading drug makers presented new data in bipolar disorder at this year's meeting of the American Psychiatric Association. Despite Cephalon's Nuvigil showing promise as an adjunct, modest data for antipsychotics from Merck & Co and Pfizer served only to highlight the remaining unmet needs in the treatment of this disease.

Published By Datamonitor
08 Jun 2010
Expert View
Expert View

APA 2010: Merck and Dainippon take center stage to present new schizophrenia therapies

Schizophrenia played a prominent role at this year's American Psychiatric Association Annual Meeting due to the prevailing high level of unmet need. Merck & Co and Dainippon Sumitomo presented data for new drugs which Datamonitor believes represent important additions to the current treatment portfolio. Elsewhere, an interesting lecture predicted a future of personalized schizophrenia treatments.

Published By Datamonitor
08 Jun 2010
Expert View
Expert View

APA 2010: new long-term data confirm potential of depot formulations

Bringing improved patient compliance, depot formulations tackle a crucial unmet need in schizophrenia and the FDA approval of Invega Sustenna and Zyprexa Relprevv represent important steps to improve the transparency of compliance. At this year's American Psychiatric Association meeting, both Johnson & Johnson and Eli Lilly presented data of these depots' long-term efficacy and safety.

Published By Datamonitor
10 Jun 2010
Expert View
Expert View

APA 2010: unmet needs in major depressive disorder remain key

Key themes presented in the field of major depressive disorder at this year's American Psychiatric Association annual meeting included treatment-resistant depression, transcranial magnetic stimulation and adjunctive use of antipsychotics. While no new clinical trial data were presented, those that were provide an interesting insight into the strategies of a number of major pharmaceutical players.

Published By Datamonitor
10 Jun 2010
Expert View
Expert View

APA meeting 2009: clinical data support potential label expansions in GAD

In May 2009, Datamonitor attended the annual American Psychiatric Association meeting in San Francisco. At the conference, AstraZeneca and Pfizer presented data for two high-profile products for which they hope to gain label expansions into generalized anxiety disorder. However, both companies have found pursuing this expansion to be challenging.

Published By Datamonitor
29 May 2009
Expert View
Expert View

APA meeting 2009: new schizophrenia products and depot formulations

The annual meeting of the American Psychiatric Association is the year's largest psychiatry event. This year's conference in San Francisco indicated that long-acting depot versions of atypical antipsychotics continue to prove useful tools in the treatment of schizophrenia. In addition, new potential market entrants reported mixed data from new oral antipsychotics.

Published By Datamonitor
29 May 2009
Expert View
Expert View

APA meeting 2009: novel drugs face challenges in mature depression and bipolar markets

At the recent meeting of the American Psychiatric Association, Forest/Gedeon Richter and Lundbeck attracted attention following the presentation of positive data for two novel drugs in bipolar disorder and depression, respectively. Given that both these indications are highly competitive and genericized markets, the companies are already seeking to differentiate their respective products.

Published By Datamonitor
29 May 2009

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.